Company Profile
Xspray Pharma AB (publ), a pharmaceutical company develops protein kinase inhibitors for targeted cancer treatments in Sweden. The company develops Dasynoc, an amorphous version of dasatinib for the treatment of chronic myeloid leukemia (CML)and acute lymphoblastic leukemia.
Its portfolio also includes XS003, an amorphous non-crystalline nilotinib for the treatment of CML, XS008, an axitinib for the treatment of kidney cancer, and XS025, a amorphous non-crystalline cabozantinib for the treatment of renal cell carcinoma and cancers. It has partnership agreements with EVERSANA for the commercialization of Dasynoc. Incorporated in 2003 and headquartered in Solna, Sweden, Xspray Pharma AB (publ) was formerly known as Xspray Microparticles AB before rebranding in 2017.